---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-264582"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2021-09-02T23:59:59+00:00"
generated_at: "2026-06-29T06:00:00.141729+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acadia CFO Elena Ridloff resigns; CEO Davis named principal financial officer

## Summary
- Elena Ridloff resigned as EVP and CFO effective September 10, 2021.
- CEO Stephen Davis appointed as principal financial officer.
- Mark Schneyer appointed interim CFO; remains SVP and Chief Business Officer.

## SEC filing metadata
- accession: 0001193125-21-264582
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2021-09-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312521264582/0001193125-21-264582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312521264582/d206699d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-264582
- JSON: https://secwatch.observer/filing/0001193125-21-264582.json
- Plain text: https://secwatch.observer/filing/0001193125-21-264582.txt

## Key facts
- Executive change
  Elena Ridloff resigned as Executive Vice President and Chief Financial Officer at ACADIA PHARMACEUTICALS INC.
  - Action: resigned
  - Role: Executive Vice President and Chief Financial Officer
  source text: Elena Ridloff gave notice on August 30, 2021 of her resignation as Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals Inc. (the “Company”), effective September 10, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312521264582/0001193125-21-264582-index.htm
- Executive change
  Stephen Davis was appointed as principal financial officer at ACADIA PHARMACEUTICALS INC.
  - Action: appointed
  - Role: principal financial officer
  source text: On August 31, 2021, the Board of Directors of the Company (the “Board”) appointed Stephen Davis, the Company’s Chief Executive Officer, as the Company’s principal financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312521264582/0001193125-21-264582-index.htm
- Executive change
  Mark Schneyer was appointed as interim Chief Financial Officer at ACADIA PHARMACEUTICALS INC.
  - Action: appointed
  - Role: interim Chief Financial Officer
  source text: The Board also appointed Mark Schneyer as the Company’s interim Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312521264582/0001193125-21-264582-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.